Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other Events
Item 8.01 Other Events.
Tyme Technologies, Inc. (OTC QB: TYMI)(the Company), a
clinical-stage pharmaceutical company focused on discovering and
developing highly targeted cancer therapeutics for a broad range
of oncology indications, announced that it raised $1.47 million
through a private placement of 452,309 shares of its common
stock.
About Tyme
Tyme Technologies is developing a novel first-in-class therapy,
SM-88, that is designed to use cancers unusual metabolism to
selectively break down the cellular defenses of tumors, leading
to tumor cell death. To date, SM-88 has been used in over 84
patients and shown a clinical response in thirteen cancer types.
In its initial Phase I trial for end-stage, metastatic patients,
SM-88 monotherapy resulted in a median overall survival of 26
months and 32% patients alive at the end of the three year
evaluation period without a single drug-related serious adverse
event. The Company is currently conducting a Phase Ib/II trial in
prostate cancer in addition to ongoing collaborations with the
Mayo Clinic, Mount Sinai, the Albert Einstein College of Medicine
and other institutions. For more information, visit our website:
www.tymetechnologiesinc.com.
Safe Harbor Statement
This report on Form 8-K contains forward-looking statements.
Readers can identify forward-looking statements by sentences or
passages involving the use of terms such as anticipates,
believes, designed, could, estimates, expects, intends, may,
plans, potential, predicts, projects, should, would and similar
expressions intended to identify forward-looking statements.
Forward-looking statements within this press release include,
without limitation, statements regarding our drug development
strategies, the therapeutic mechanisms and potential side effects
of our drug candidates and our planned clinical trials and
operational objectives. These statements involve known and
unknown risks, uncertainties and other factors which may cause
the Companys actual results, performance or achievements to be
materially different from any historical results and future
results, performances or achievements expressed or implied by the
forward-looking statements. These risks and uncertainties
include, but are not limited to, the factors described in the
section captioned Risk Factors of Tymes Annual Report on Form
10-K filed with the U.S. Securities and Exchange Commission on
March 30, 2016 (available at www.sec.gov).
Forward-looking statements reflect Tymes current views with
respect to future events and are based on assumptions and subject
to risks and uncertainties. We are not necessarily obligated to
update any forward-looking statement due to any change or
development that occurs or may occur after the disclosure of such
a statement. Given these uncertainties, readers should not place
undue reliance on these forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Certain presentation materials provided to investors in the
private placement described above are furnished as Exhibit 99.1
to this Form 8-K.
|
Exhibit Number |
Description of Exhibit |
|
|
99.1 |
Investor Presentation December 2016 |
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue. Tyme Technologies, Inc. (OTCMKTS:TYMI) Recent Trading Information
Tyme Technologies, Inc. (OTCMKTS:TYMI) closed its last trading session up +1.35 at 3.05 with 231,308 shares trading hands.